Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 9/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26807751 | 0.88 | GUSB (0.41) | GUSBFLT3NMT1HTR6PLA2G7 | |
| SCHEMBL26807728 | 0.88 | FLT3 (0.37) | GUSBFLT3HTR6LTA4HRIPK2 | |
| SCHEMBL26807760 | 0.88 | LTA4H (0.48) | GUSBNMT1HTR6PLA2G7LTA4H | |
| SCHEMBL26807769 | 0.87 | GUSB (0.43) | GUSBHTR6LTA4H | |
| SCHEMBL24309513 | 0.87 | LTA4H (0.41) | GUSBFLT3NMT1HTR6PLA2G7 | |
| SCHEMBL26807780 | 0.87 | LTA4H (0.47) | GUSBFLT3HTR6LTA4HRIPK2 | |
| SCHEMBL29567157 | 0.87 | LTA4H (0.41) | GUSBFLT3NMT1HTR6PLA2G7 | |
| SCHEMBL24310583 | 0.86 | RIPK2 (0.38) | GUSBFLT3HTR6BRD4LCK | |
| SCHEMBL24309665 | 0.86 | GUSB (0.39) | GUSBFLT3NMT1HTR6PLA2G7 | |
| SCHEMBL29566865 | 0.86 | GUSB (0.39) | GUSBFLT3NMT1HTR6PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | GUSB 2723/4885FLT3 4133/4885NMT1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.